NEW YORK (TheStreet) -- Endo Int'l (ENDP) - Get Report stock is up 19.43% to $16.35 on heavy trading volume this afternoon after one of its operating companies, Par Pharmaceuticals, was issued a patent by the FDA for a vasopressin injection drug, Vasostrict.
About 14.8 million shares of the Malvern, PA company's stock had traded hands by late afternoon today, vs. the average of 9 million shares per day.
Vasostrict is the first vasopressin injection product approved by the FDA.
Intended for adults suffering from vasodilatory shock that can't be helped with administration of fluids and catecholamines, Vasostrict increases a patient's blood pressure.
Separately, TheStreet Ratings rated this stock as a "sell" with a ratings score of D.
The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.
You can view the full analysis from the report here: ENDP
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.